FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4225726483> ?p ?o ?g. }

• W4225726483 endingPage "5" @default.
• W4225726483 startingPage "1" @default.
• W4225726483 abstract "Retrospective analysis of the effects of febuxostat on urine neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule-1 (KIM-1) in patients with hyperuricemia was performed. From January 2018 to June 2018, there were 45 patients with asymptomatic hyperuricemia in the outpatient or inpatient of Changzhou Second People's Hospital, which were divided into the febuxostat group (25 cases) and the control group (20 cases). We collected the patients' baseline indicators and testing indicators after three months of treatment, including blood urea nitrogen, blood creatinine, blood uric acid, urine microalbumin, urine NGAL, urine KIM-1, and other indicators. The subjects in both groups were given lifestyle intervention, instructed to drink more water, and given a low-purine diet. The patients in the febuxostat group took febuxostat 40 mg/D or 80 mg/D. We used SPSS 25.0 statistical software for statistical analysis. Baseline indexes between the febuxostat group and the control group and indexes after treatment between two groups were both performed by independent sample t-test, and paired t-test was used for self-comparison between the groups before and after treatment. There was no significant difference in age, sex, body mass index (BMI), urea nitrogen, creatinine, uric acid, urine microalbumin/creatinine, urine NGAL/creatinine, and urine KIM-1/creatinine between the two groups before treatment (P > 0.05). Compared with before treatment, after 3 months of intervention, the levels of serum uric acid, urine microalbumin/creatinine, urine NGAL/creatinine, and urine KIM-1/creatinine were significantly decreased in the febuxostat group (P < 0.05), while the changes of blood urea nitrogen, serum creatinine, and epidermal growth factor receptor (eGFR) were not statistically significant (P > 0.05). After 3 months of intervention, the control group had no significant changes in blood urea nitrogen, creatinine, eGFR, uric acid, microalbumin/creatinine, urine NGAL/creatinine, and urine KIM-1/creatinine (P > 0.05). After 3 months of intervention, compared with the control group, the serum uric acid, microalbumin/creatinine, urine NGAL/creatinine, and urine KIM-1/creatinine were significantly decreased in the febuxostat group (P < 0.05), but there was no significant difference in blood urea nitrogen, creatinine, and eGFR (P > 0.05). Febuxostat can reduce urine NGAL/creatinine and urine KIM-1/creatinine levels in patients with hyperuricemia and has the protective effects on renal tubular injury caused by hyperuricemia, which can provide evidences for the early prevention and treatment of asymptomatic hyperuricemia." @default.
• W4225726483 created "2022-05-05" @default.
• W4225726483 creator A5024267153 @default.
• W4225726483 creator A5038566451 @default.
• W4225726483 creator A5070632812 @default.
• W4225726483 creator A5086499413 @default.
• W4225726483 date "2022-04-04" @default.
• W4225726483 modified "2023-09-26" @default.
• W4225726483 title "The Effects of Febuxostat on Urine NGAL and Urine KIM-1 in Patients with Hyperuricemia" @default.
• W4225726483 cites W1499216809 @default.
• W4225726483 cites W1969455198 @default.
• W4225726483 cites W1990544066 @default.
• W4225726483 cites W2015336570 @default.
• W4225726483 cites W2027904647 @default.
• W4225726483 cites W2108187770 @default.
• W4225726483 cites W2122983268 @default.
• W4225726483 cites W2126653200 @default.
• W4225726483 cites W2136066292 @default.
• W4225726483 cites W2145422652 @default.
• W4225726483 cites W2156131531 @default.
• W4225726483 cites W2165728924 @default.
• W4225726483 cites W2172018609 @default.
• W4225726483 cites W2282083919 @default.
• W4225726483 cites W2460049888 @default.
• W4225726483 cites W2809237421 @default.
• W4225726483 cites W2907934371 @default.
• W4225726483 doi "https://doi.org/10.1155/2022/6028611" @default.
• W4225726483 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35419185" @default.
• W4225726483 hasPublicationYear "2022" @default.
• W4225726483 type Work @default.
• W4225726483 citedByCount "1" @default.
• W4225726483 countsByYear W42257264832023 @default.
• W4225726483 crossrefType "journal-article" @default.
• W4225726483 hasAuthorship W4225726483A5024267153 @default.
• W4225726483 hasAuthorship W4225726483A5038566451 @default.
• W4225726483 hasAuthorship W4225726483A5070632812 @default.
• W4225726483 hasAuthorship W4225726483A5086499413 @default.
• W4225726483 hasBestOaLocation W42257264831 @default.
• W4225726483 hasConcept C126322002 @default.
• W4225726483 hasConcept C126894567 @default.
• W4225726483 hasConcept C159641895 @default.
• W4225726483 hasConcept C2779225474 @default.
• W4225726483 hasConcept C2779721657 @default.
• W4225726483 hasConcept C2779881121 @default.
• W4225726483 hasConcept C2780026642 @default.
• W4225726483 hasConcept C2780306776 @default.
• W4225726483 hasConcept C2780932893 @default.
• W4225726483 hasConcept C71924100 @default.
• W4225726483 hasConceptScore W4225726483C126322002 @default.
• W4225726483 hasConceptScore W4225726483C126894567 @default.
• W4225726483 hasConceptScore W4225726483C159641895 @default.
• W4225726483 hasConceptScore W4225726483C2779225474 @default.
• W4225726483 hasConceptScore W4225726483C2779721657 @default.
• W4225726483 hasConceptScore W4225726483C2779881121 @default.
• W4225726483 hasConceptScore W4225726483C2780026642 @default.
• W4225726483 hasConceptScore W4225726483C2780306776 @default.
• W4225726483 hasConceptScore W4225726483C2780932893 @default.
• W4225726483 hasConceptScore W4225726483C71924100 @default.
• W4225726483 hasLocation W42257264831 @default.
• W4225726483 hasLocation W42257264832 @default.
• W4225726483 hasLocation W42257264833 @default.
• W4225726483 hasOpenAccess W4225726483 @default.
• W4225726483 hasPrimaryLocation W42257264831 @default.
• W4225726483 hasRelatedWork W1503738388 @default.
• W4225726483 hasRelatedWork W2127783110 @default.
• W4225726483 hasRelatedWork W2161814120 @default.
• W4225726483 hasRelatedWork W2373610748 @default.
• W4225726483 hasRelatedWork W2415262299 @default.
• W4225726483 hasRelatedWork W2527290573 @default.
• W4225726483 hasRelatedWork W3086123519 @default.
• W4225726483 hasRelatedWork W3116844873 @default.
• W4225726483 hasRelatedWork W4225726483 @default.
• W4225726483 hasRelatedWork W4385857717 @default.
• W4225726483 hasVolume "2022" @default.
• W4225726483 isParatext "false" @default.
• W4225726483 isRetracted "false" @default.
• W4225726483 workType "article" @default.